Total Payments
$6,184
2024 Payments
$1,210
Companies
39
Transactions
356
Medicare Patients
3,884
Medicare Billing
$171,468
Payment Breakdown by Category
Food & Beverage$5,824 (94.2%)
Education$340.63 (5.5%)
Other$18.80 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,824 | 351 | 94.2% |
| Education | $340.63 | 4 | 5.5% |
| Debt forgiveness | $18.80 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,536 | 123 | $0 (2024) |
| Astellas Pharma US Inc | $560.26 | 17 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $369.99 | 5 | $0 (2024) |
| Lilly USA, LLC | $344.96 | 26 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $342.29 | 19 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $255.63 | 15 | $0 (2024) |
| Novo Nordisk Inc | $209.40 | 21 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $203.92 | 10 | $0 (2023) |
| ITI, Inc. | $189.45 | 3 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $176.64 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,210 | 62 | ABBVIE INC. ($307.30) |
| 2023 | $1,605 | 68 | ABBVIE INC. ($529.50) |
| 2022 | $2,193 | 156 | ABBVIE INC. ($355.59) |
| 2021 | $1,176 | 70 | AbbVie Inc. ($343.94) |
All Payment Transactions
356 individual payment records from CMS Open Payments — Page 2 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.08 | General |
| Category: NEUROSCIENCE | ||||||
| 07/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.79 | General |
| Category: NEUROSCIENCE | ||||||
| 07/01/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: NEUROSCIENCE | ||||||
| 05/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.34 | General |
| Category: NEUROSCIENCE | ||||||
| 05/22/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $28.50 | General |
| Category: Genetic Disease | ||||||
| 05/13/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: Inflammation | ||||||
| 05/09/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $99.79 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $11.71 | General |
| Category: NEUROSCIENCE | ||||||
| 05/06/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Diabetes | ||||||
| 05/02/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: Genetic Disease | ||||||
| 04/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Respiratory | ||||||
| 04/29/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $3.72 | General |
| Category: NEUROSCIENCE | ||||||
| 04/25/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: NEUROSCIENCE | ||||||
| 04/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: NEUROSCIENCE | ||||||
| 04/04/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Respiratory | ||||||
| 04/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.63 | General |
| Category: NEUROSCIENCE | ||||||
| 03/24/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $12.26 | General |
| Category: NEUROSCIENCE | ||||||
| 03/22/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $3.48 | General |
| Category: NEUROSCIENCE | ||||||
| 03/15/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: PSYCHIATRY | ||||||
| 03/15/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $9.34 | General |
| Category: NEUROSCIENCE | ||||||
| 03/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: NEUROSCIENCE | ||||||
| 03/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.14 | General |
| Category: NEUROSCIENCE | ||||||
| 02/22/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $5.26 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 1,079 | 1,936 | $120,249 | $49,303 |
| 2022 | 26 | 1,410 | 2,274 | $153,440 | $65,556 |
| 2021 | 21 | 837 | 1,163 | $79,941 | $37,511 |
| 2020 | 18 | 558 | 740 | $54,701 | $19,098 |
Total Patients
3,884
Total Services
6,113
Medicare Billing
$171,468
Procedure Codes
88
All Medicare Procedures & Services
88 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 243 | 458 | $45,800 | $22,431 | 49.0% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 32 | 180 | $13,500 | $6,463 | 47.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 76 | 96 | $14,784 | $6,462 | 43.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 32 | 32 | $7,552 | $3,415 | 45.2% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 29 | 29 | $2,900 | $1,505 | 51.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 116 | 172 | $1,720 | $1,445 | 84.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 12 | 12 | $960.00 | $863.16 | 89.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 58 | 100 | $4,000 | $846.30 | 21.2% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 57 | 64 | $3,328 | $839.68 | 25.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 66 | 79 | $6,715 | $817.65 | 12.2% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 37 | 42 | $2,646 | $691.32 | 26.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 68 | 90 | $2,700 | $684.90 | 25.4% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 15 | 16 | $1,280 | $553.92 | 43.3% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 29 | 29 | $870.00 | $440.51 | 50.6% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 16 | 18 | $1,350 | $355.04 | 26.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 12 | 12 | $360.00 | $352.80 | 98.0% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 36 | 39 | $2,535 | $323.31 | 12.8% |
| 74019 | X-ray of abdomen, 2 views | Office | 2023 | 13 | 13 | $975.00 | $292.32 | 30.0% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 24 | 28 | $1,064 | $266.56 | 25.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 34 | 162 | $1,620 | $114.95 | 7.1% |
| 81003 | Automated urinalysis test | Office | 2023 | 27 | 45 | $630.00 | $99.00 | 15.7% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 18 | 80 | $1,840 | $28.98 | 1.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 29 | 140 | $1,120 | $11.27 | 1.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 381 | 635 | $63,500 | $32,482 | 51.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 106 | 136 | $20,944 | $9,634 | 46.0% |
About Patrick Smith, RN, FNP
Patrick Smith, RN, FNP is a Family healthcare provider based in Wake Village, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1417949801.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Patrick Smith, RN, FNP has received a total of $6,184 in payments from pharmaceutical and medical device companies, with $1,210 received in 2024. These payments were reported across 356 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($5,824).
As a Medicare-enrolled provider, Smith has provided services to 3,884 Medicare beneficiaries, totaling 6,113 services with total Medicare billing of $171,468. Data is available for 4 years (2020–2023), covering 88 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Wake Village, TX
- Active Since 08/22/2005
- Last Updated 11/10/2009
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1417949801
Products in Payments
- VRAYLAR (Drug) $582.11
- QULIPTA (Drug) $512.43
- UBRELVY (Drug) $441.79
- XARELTO (Drug) $369.99
- TRINTELLIX (Drug) $310.78
- Kerendia (Drug) $203.92
- CAPLYTA (Drug) $189.45
- NURTEC ODT (Drug) $166.20
- JARDIANCE (Drug) $161.35
- TRELEGY ELLIPTA (Drug) $153.12
- VOQUEZNA (Drug) $148.02
- BELSOMRA (Drug) $147.80
- Veozah (Drug) $139.09
- FARXIGA (Drug) $135.16
- GIMOTI (Drug) $122.30
- ENTRESTO (Drug) $117.39
- MOUNJARO (Drug) $116.86
- TRULICITY (Drug) $105.14
- Rybelsus (Drug) $97.19
- Impella (Device) $88.67
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.